Hello!
Was pleased to find that this Finnish article is from 2008, that I did not succeed in finding in full text some years ago. THANKS!! I slogged my way through it today because I wanted to see what data it actually contained. A few years ago I had my partial genome sequenced by 23andme, which included data for SNPs of this gene, with result that I have very low/average likehood of adverse effects from statins, specifically simvastatin. Figure 13, way back in latter part of this article, shows the data for three SNPs of this gene, for simvastatin. 23andme reports that I and my two daughters all have the TT genotype, which is the one that shows little contribution/incidence of adverse effects.
![Exclamation :!:](./images/smilies/icon_exclaim.gif)
BUT!! I still had plenty of quite adverse effects.
![Exclamation :!:](./images/smilies/icon_exclaim.gif)
SO, that leaves at least two or lots more open issues. First is that I took Lipitor, not simvastatin -- perhaps not much of difference, at least in relative effects for each SNP. Second and the wide open, obvious issues -- there is lots more to this than just this one gene and its SNPs, etc.
We really should not be too surprised that this one gene and its SNPs are no more than a part of the entire picture, ditto for the "CoQ10" gene. Consider, for example, all the biochemical processes that statins adversely affect. Then ask "What genes and which of their SNPs and other mutations "control" each of these processes?" I would not be surprised if the total number of possible "guilty" genes and their mutations is well into 10s and 10s. And that does not include any "regulator/on-off genes".
It is really nice to see progress in this area, makes me hungry for more, and more, and more.
Lars